Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Biol Psychiatry. 2014 Apr 25;77(5):475–487. doi: 10.1016/j.biopsych.2014.04.009

Figure 9. Impact of paclitaxel and AM1710 on cytokine and chemokine mRNA levels in lumbar spinal cord.

Figure 9

(A) Paclitaxel increased the spinal mRNA levels of MCP-1, but not IL-1β, IL-6, or TNFα relative to cremophor in WT mice (day 15 post initial paclitaxel dosing). (B) Both acute (once daily injections of vehicle × 7 days followed by a terminal injection of AM1710 (5 mg/kg i.p.) on the 8th day, grey bar) and chronic (5 mg/kg/day i.p. × 8 days, black bar) administrations of AM1710 decreased the spinal mRNA levels of TNFα and MCP-1, but not IL-1β or IL-6 relative to vehicle (once daily × 8 days, white bar) in paclitaxel-treated WT animals. IL-1β, interleukin-1 beta; IL-6, interleukin 6; TNFα, tumor necrosis factor alpha; MCP-1, monocyte chemoattractant protein-1. Data are expressed as mean ± SEM (n=4 per group). #P<0.05 vs. cremophor vehicle in lieu of paclitaxel, one-tailed t-test. *P<0.05 vs. vehicle in lieu of AM1710, one-way ANOVA followed by Bonferroni post hoc test.